Lilly studying how dogs sense diabetes in humans
The Indianapolis drugmaker said its scientists are investigating whether dogs' sharp sense of smell allow them to detect changes in human chemistry.
Eli Lilly and Co.
Articles
Lilly braces for decline in Europe
Austerity and upheaval in Europe have not hurt Eli Lilly and Co.’s $4 billion-a-year drug business there, but the company is moving forward with plans to survive a coming swoon anyway.
Lilly’s quarterly profit falls, but tops analyst expectations
Eli Lilly and Co. reported second-quarter profit that fell less than analysts had expected. The company raised its outlook for the rest of the year.
Potential Alzheimer’s drug fails first of four key trials
Bapineuzumab is in a race with a similar product from Indianapolis-based Eli Lilly and Co. to become the first therapy to target a cause for Alzheimer’s, rather than just its symptoms.
Potential Lilly antipsychotic falls short in study
Eli Lilly and Co. said a potential treatment for acute schizophrenia failed in a late-stage study that compared patients taking the drug to those taking a placebo.
Competing Alzheimer’s treatments facing long odds
Johnson & Johnson, Pfizer Inc. and Elan Corp are racing Indianapolis-based Eli Lilly and Co. to market the first broadly available drug designed to target a cause of Alzheimer’s, rather than just its symptoms. Analysts say the potential drugs are long shots.
Lilly gets 6-month Cymbalta marketing extension
Eli Lilly and Co. said Friday that it has received an extra six months of marketing exclusivity on the antidepressant Cymbalta, its biggest selling drug. The extension could mean more than a billion dollars in sales for the Indianapolis drug maker.
Lilly cancer treatment fails trial in stomach cancer
Erbitux, a cancer treatment made by Indianapolis-based Eli Lilly and Co.'s Imclone unit, failed to help patients with advanced stomach tumors in a late-stage clinical trial.
Bristol-Myers to buy former Lilly partner Amylin for $5.3B
Bristol-Myers Squibb Co. has agreed to pay $5.3 billion to acquire former Eli Lilly and Co. partner Amylin Pharmaceuticals Inc., a maker of diabetes therapies. The deal is valued at about $7 billion, which includes Amylin’s debt and a payment to Eli Lilly and Co. of about $1.7 billion.
Life sciences hold up in recession
A new report shows Indiana’s life sciences companies performed better than their peers around the country—and far better than the rest of Indiana’s private sector—during the early phases of the economic downturn.
Analysis: How stocks will fare in ruling on health care law
The Supreme Court is expected to rule on the Affordable Care Act by the end of June. Here’s a roundup of how health care businesses would be affected under four different scenarios.
J&J, Bayer fail to win U.S. OK for expanded Xarelto use
If approved for acute coronary syndrome, Xarelto would compete with Effient from Indianapolis-based Eli Lilly and Co and Brilinta from London-based AstraZeneca Plc.
Lilly resumes $3B stock buyback program, declares dividend
The local pharmaceutical giant plans to complete the program started in 2000 by repurchasing $420 million in shares by the end of the year. And on Tuesday, it declared a regular dividend of 49 cents.
Web domain requests include .Cialis, .Walmart
Indianapolis-based Eli Lilly and Co. and other corporate heavyweights are applying for Web suffixes including .cialis, .walmart and .jpmorgan under a program to expand the number of Internet domain names beyond .com.
Largest Indiana public companies mostly fared well in 2011
Performance varied widely as industries ebbed, flowed.
Lilly sinks $20M into Chinese firm for ‘branded generic’ drugs
Eli Lilly and Co. has invested $20 million in Chinese pharmaceutical company Novast Labs in an effort to build up a portfolio of branded generic medicines in the fast-growing Asian market.
Lilly chases Novo in insulin race
Eli Lilly and Co. announced positive results for an experiemental insulin at the annual American Diabetes Association conference in Philadelphia, but was still upstaged by Denmark-based Novo Nordisk A/S.
Good cholesterol may not lower heart risk, study suggests
Raising good cholesterol, a goal pursued by Eli Lilly and Co. as the next milestone in cardiac care, may not cut heart-attack risk, says a study that challenges the development of drugs that may someday generate billions of dollars in sales.
U.S. losing drug-research jobs to other countries
Eli Lilly and other big pharmaceutical companies are creating thousands of research jobs overseas as countries led by Singapore, Ireland and South Africa boost incentives.
Lilly unlikely to gain from Plavix patent loss, analyst says
Indianapolis-based Eli Lilly and Co. and London-based AstraZeneca Plc aren't expected to have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co.’s Plavix after the drug loses U.S. patent protection Thursday.